… Loncastuximab tesirine (ADCT-402) is an antibody-drug … As demonstrated in this study,
loncastuximab tesirine has … A phase I study of ADCT-402 (loncastuximab tesirine), a novel …

… , phase II trial included 145 patients with relapsed/ refractory … has been observed with
ADCT-402 [Citation57], study of other … Loncastuximab tesirine is an antibody drug conjugate that …

… B-cell lymphoma, ADCT-402, antibody–drug conjugate, loncastuximab tesirine and non-Hodgkin's
lymphoma… -5 are positive, then the value of loncastuximab tesirine as a novel anti-R/R …

… subtype of non-Hodgkin lymphoma. Relapsed/refractory disease represents remains an …
of the anti-CD19 ADC ADCT-402 (loncastuximab tesirine) containing the PBD dimer payload …

… Loncastuximab tesirine (also known as ADCT-402) is an … in non-Hodgkin lymphoma (NHL),
and a phase 2 trial has been … Loncastuximab tesirine is a novel CD19-targeted humanized …

… its role in both frontline as well as relapsed refractory setting. … A phase I study of ADCT-402
(loncastuximab tesirine), a novel pyrrolobenzodiazepine-based antibody-drug conjugate, in …

… A phase I study of ADCT-402 (loncastuximab tesirine), a novel pyrrolobenzodiazepine-based
antibody-drug conjugate, in … in relapsed/refractory B-cell non-Hodgkin lymphoma. …

… [ADCT-402]) (Katz and Herishanu 2014; Narkhede and Tafasitamab … relapsed/refractory
setting in other forms of B-cell NHL. Like tafasitamab, loncastuximab tesirine has been studied in …

… and phase II experimental studies in non-Hodgkin's lymphoma… means antibodies of
antibody-drug conjugate targeted binding … ADCT-402 is a good choice for relapsed/ refractory …

… in relapsed/refractory B-cell non-Hodgkin lymphoma … initial results of a phase 2 study
of loncastuximab tesirine, a novel pyrrolobenzodiazepine-based antibody-drug conjugate …